Recombinant Human FGF-20 Protein, CF

Recombinant Human FGF-20 Protein, CF Protein (Catalog # 2547-FG/CF) stimulates proliferation of Balb/3T3 mouse embryonic fibroblast cells in the presence of heparin. The ED50 for this effect is 10.0-100 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human FGF-20 Protein, CF Summary

• Details of Functionality:

  Measured in a cell proliferation assay using Balb/3T3 mouse embryonic fibroblast cells in the presence of heparin. The ED₅₀ for this effect is 10.0-100 ng/mL.

• Source: E. coli-derived human FGF-20 protein
  Ala2-Thr211, with an N-terminal Met and a 6-His tag
• Accession #: Q9NP95
• N-terminal Sequence: Met
• Protein/Peptide Type: Recombinant Proteins
• Gene: FGF20
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 24 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MOPS, (NH₄)₂SO₄, DTT and EDTA.
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human FGF-20 Protein, CF

• FGF20
• FGF-20
• fibroblast growth factor 20

Background

Fibroblast growth factor 20 (FGF-20) is a member of the FGF gene family, which currently contains 22 members. Based on its structure, it is further classified as an FGF-9 subfamily member. All FGF family members are heparin-binding growth factors with a 120 amino acid (aa) core FGF domain that exhibits a beta -trefoil structure (1). The cDNA of FGF-20 predicts a 211 aa polypeptide without a canonical signal peptide sequence, a feature shared with other members of this subfamily (2-4). Nevertheless, it is secreted with a molecular weight of 27 kDa (2-4). FGF-20 is known to bind to heparin (4). No alternate splice forms have been reported. However, three amino acid polymorphisms are known, and single nucleotide polymorphisms in noncoding regions that may effect expression show a strong correlation with a risk of developing Parkinson’s disease (5, 6). Human FGF-20 shows 98% aa identity to bovine FGF-20 and 95% aa identity to both rat and mouse FGF-20. Within the FGF-9 subfamily, FGF-20 is 69% and 63% aa identical to human FGF-9 and FGF-16, respectively. Human FGF-20 is reported to be promiscuous in its selection of receptors which include FGF R1c, FGF R2c, FGF R3b, FGF R3c and FGF R4 (4, 7, 8). FGF-20 is expressed a variety of cells, including dopaminergic neurons (2), fibroblasts, keratinocytes and breast epithelium (4), and multiple sites in the fetus (2, 7). Finally, the expression of FGF-20 and DKK-1 is regulated by beta -catenin during development and tumorigenesis, implying that FGF-20 may play a role in the oncogenesis induced by the Wnt signaling pathway (9).

1. Itoh, N. and D.M. Ornitz (2004) Trends Genet. 20:563.
2. Ohmachi, S. et al. (2000) Biochem. Biophys. Res. Commun. 277:355.
3. Kirikoshi, H. et al. (2000) Biochem. Biophys. Res. Commun. 274:337.
4. Jeffers, M. et al. (2001) Cancer Res. 61:3131.
5. van der Walt, J. et al. (2004) Am. J. Hum. Genet. 74:1121.
6. Genbank Accession # Q9NP95.
7. Lavine, K.J. et al. (2005) Dev. Cell 8:85.
8. Ohmachi, S. et al. (2003) J. Neurosci. Res. 72:436.
9. Chamorro, M.N. et al. (2005) EMBO J. 24:73.

Publications for FGF-20 (2547-FG/CF)(5)

Publications using 2547-FG/CF

• Ku Y, Renaud N, Veile R, Helms C, Voelker C, Warchol M, Lovett M The transcriptome of utricle hair cell regeneration in the avian inner ear. J Neurosci, 2014-03-05;34(10):3523-35. 2014-03-05 [PMID: 24599453] (Bioassay, Chicken)
• Hong , Weimin C, Amara , Susan G Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons. FASEB J, 2013-04-23;27(8):2995-3007. 2013-04-23 [PMID: 23612789] (Bioassay, Rat)
• Tomlinson DC, Knowles MA Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am. J. Pathol., 2010-10-01;177(5):2379-86. 2010-10-01 [PMID: 20889570] (Bioassay, Human)
• Hayashi T, Ray CA, Bermingham-McDonogh O Fgf20 is required for sensory epithelial specification in the developing cochlea. J. Neurosci., 2008-06-04;28(23):5991-9. 2008-06-04 [PMID: 18524904] (Bioassay, Mouse)
• Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, Scott WK, Martin ER, Vance JM Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet., 2008-01-31;82(2):283-9. 2008-01-31 [PMID: 18252210] (Bioassay, Human)

Bioinformatics

• Gene Symbol: FGF20
• Uniprot:
  • Q9NP95()